02808nas a2200241 4500008004100000245018600041210006900227260001800296300001000314490000600324520203800330653001702368653001002385653002002395653001802415653003102433653002002464100000502484700000502489700000502494700002702499856004002526 2014 eng d00aStandardization of a polyherbal formulation (HC9) and comparative analysis of its cytotoxic activity with the individual herbs present in the composition in breast cancer cell lines0 aStandardization of a polyherbal formulation HC9 and comparative  c18th Feb,2014 a87-950 v63 a

Introduction: The present study aims to standardize a polyherbal formulation (HC9) that was previously shown to exhibit excellent antioxidant and cytotoxic activity in breast cancer cells. Here, we have compared the cytotoxic activity of HC9 with its individual components in breast cancer and non-cancerous cells. Methods: Physico-chemical and phytochemical evaluation of HC9 was performed. Qualitative and quantitative HPTLC analysis of component herbs and HC9 was done by using specific markers. The cytotoxic activity of HC9 with its individual components was evaluated in breast cancer (MCF-7 and MDA MB-231) and non-cancerous cell lines (HEK-293, HaCaT and MCF-10A) by MTT dye uptake. Results: Physico-chemical results revealed that HC9 contained 7.24% total ash content, 9.52% of alcohol-soluble extractive, 0.801 specific gravity, 0.50g/ml bulk density and exhibited 7.18% loss on drying. Phytochemical results revealed the presence of alkaloids, carbohydrates, flavanoids, saponins, tannins and phenolic compounds, and absence of terpenoids. The individual herbs of HC9 and the formulation showed the presence of marker compounds such as picroside-I, nootkatone, 6-gingerol, matairesinol, swertiamarin, berberine, connesine and 2-hydroxy-4-methoxybenzaldehyde. At 160μg/ml concentration, HC9 exhibited cytotoxicity in both MCF7 and MDA MB231 with no cytotoxicity in MCF-10A, HaCaT and HEK-293. In contrast, at this concentration, the individual herbs of HC9 exhibited cytotoxicity not only in cancerous cells, but also in non-cancerous cells. Conclusion: These results suggest that the standardized HC9 formulation was safe to non-cancerous cells and exhibited significant antineoplastic potential in breast cancer cells. Thus, HC9 could be a potential drug candidate in breast cancer.

Key words: Cytotoxicity, HPTLC, physicochemical, polyherbal formulation HC9, phytochemical, standardization.

10aCytotoxicity10aHPTLC10aPhysicochemical10aPhytochemical10apolyherbal formulation HC910astandardization1 a1 a1 a1 aKaul-Ghanekar, Ruchika uhttps://www.phcogj.com/article/1552